Genomic medicine frontier in human solid Tumors: Prospects and challenges

Journal of Clinical Oncology

Volumn 31, Issue 15, 2013, Pages 1874-1884

  Dienstmann, Rodrigo ^a   Rodon, Jordi ^a   Barretina, Jordi ^b   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CETUXIMAB; CRIZOTINIB; ERLOTINIB; GEFITINIB; IMATINIB; IPILIMUMAB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PANITUMUMAB; SORAFENIB; TRASTUZUMAB; VEMURAFENIB;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PATIENT; CANCER RESISTANCE; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TECHNOLOGY; GENETIC HETEROGENEITY; GENOMICS; HUMAN; MEDICINE; MOLECULARLY TARGETED THERAPY; ONCOLOGY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SOLID MALIGNANT NEOPLASM; TRANSLATIONAL RESEARCH; WHOLE EXOME SEQUENCING; GENETIC PREDISPOSITION; GENETICS; METHODOLOGY; MOLECULAR MEDICINE; MUTATION; NEOPLASM; PATHOLOGY; PERSONALIZED MEDICINE;

GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR MEDICINE; MUTATION; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

MLCS; MLOWN;

EID: 84880470045     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.2268     Document Type: Review

References (110)

1. Meyerson M, Gabriel S, Getz G: Advances in understanding cancer genomes through secondgeneration sequencing. Nat Rev Genet 11:685-696, 2010
2. Dancey JE, Bedard PL, Onetto N, et al: The genetic basis for cancer treatment decisions. Cell 148:409-420, 2012
3. Macconaill LE, Garraway LA: Clinical implications of the cancer genome. J Clin Oncol 28:5219-5228, 2010
4. Ma QC, Ennis CA, Aparicio S: Opening Pandora's Box: The new biology of driver mutations and clonal evolution in cancer as revealed by next generation sequencing. Curr Opin Genet Dev 22:3-9, 2012
5. Vucic EA, Thu KL, Robison K, et al: Translating cancer 'omics' to improved outcomes. Genome Res 22:188-195, 2012
6. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
7. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011
8. International Cancer Genome Consortium, Hudson TJ, Anderson W, et al: International network of cancer genome projects. Nature 464:993-998, 2010
9. McDermott U, Sharma SV, Dowell L, et al: Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-Throughput tumor cell line profiling. Proc Natl Acad Sci U S A 104:19936-19941, 2007
10. Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607, 2012
11. Tran B, Dancey JE, Kamel-Reid S, et al: Cancer genomics: Technology, discovery, and translation. J Clin Oncol 30:647-660, 2012
12. Mills GB: An emerging toolkit for targeted cancer therapies. Genome Res 22:177-182, 2012
13. King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974-976, 1985
14. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
15. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
16. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
17. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003
18. Liegl B, Kepten I, Le C, et al: Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216:64-74, 2008
19. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
20. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
21. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
22. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
23. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
24. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917, 2005
25. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
26. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007
27. Rikova K, Guo A, Zeng Q, et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203, 2007
28. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
29. Shaw AT, Camidge DR, Engelman JA, et al: Clinical activity of crizotinib in advanced non-small cell lung cancer harboring ROS1 gene rearrangement. J Clin Oncol 30:482s, 2012 (suppl;abstr 7508)
30. Gambacorti-Passerini C, Messa C, Pogliani EM: Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 364:775-776, 2011
31. Rudin CM, Hann CL, Laterra J, et al: Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361:1173-1178, 2009
32. Sekulic A, Migden MR, Oro AE, et al: Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366:2171-2179, 2012
33. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
34. Bookman MA, Darcy KM, Clarke-Pearson D, et al: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283-290, 2003
35. Fleming GF, Sill MW, Darcy KM, et al: Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 116:15-20, 2010
36. Kopetz S, Desai J, Chan E, et al: PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28:269s, 2010 (suppl; abstr 3534)
37. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354, 2000
38. van't Veer LJ, Bernards R: Enabling personalized cancer medicine through analysis of geneexpression patterns. Nature 452:564-570, 2008
39. Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 5:5-23, 2011
40. Curtis C, Shah SP, Chin SF, et al: The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486:346-352, 2012
41. Ledermann J, Harter P, Gourley C, et al: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382-1392, 2012
42. Kohno T, Ichikawa H, Totoki Y, et al: KIF5BRET fusions in lung adenocarcinoma. Nat Med 18: 375-377, 2012
43. Banerji S, Cibulskis K, Rangel-Escareno C, et al: Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405-409, 2012
44. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al: Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16:793-798, 2010
45. Berger MF, Lawrence MS, Demichelis F, et al: The genomic complexity of primary human prostate cancer. Nature 470:214-220, 2011
46. Berger MF, Hodis E, Heffernan TP, et al: Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485:502-506, 2012
47. Stephens PJ, Tarpey PS, Davies H, et al: The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400-404, 2012
48. Barretina J, Taylor BS, Banerji S, et al: Subtype-specific genomic alterations define new targets for soft-Tissue sarcoma therapy. Nat Genet 42:715-721, 2010
49. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008
50. Garnett MJ, Edelman EJ, Heidorn SJ, et al: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570-575, 2012
51. Cottu PH, Asselah J, Lae M, et al: Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 19:595-597, 2008
52. Shibata D: Cancer: Heterogeneity and tumor history. Science 336:304-305, 2012
53. Campbell PJ, Yachida S, Mudie LJ, et al: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467:1109-1113, 2010
54. Yachida S, Jones S, Bozic I, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114-1117, 2010
55. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012
56. Ashworth A, Lord CJ, Reis-Filho JS: Genetic interactions in cancer progression and treatment. Cell 145:30-38, 2011
57. Yap TA, Gerlinger M, Futreal PA, et al: Intratumor heterogeneity: Seeing the wood for the trees. Sci Transl Med 4:127ps10, 2012
58. Turner NC, Reis-Filho JS: Genetic heterogeneity and cancer drug resistance. Lancet Oncol 13:e178-e185, 2012
59. Liedtke C, Broglio K, Moulder S, et al: Prognostic impact of discordance between triplereceptor measurements in primary and recurrent breast cancer. Ann Oncol 20:1953-1958, 2009
60. Niikura N, Liu J, Hayashi N, et al: Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30:593-599, 2012
61. Vakiani E, Janakiraman M, Shen R, et al: Comparative genomic analysis of primary versus metastasis in colorectal carcinomas. J Clin Oncol 29:630s, 2011 (suppl; abstr 10500)
62. Jakobsen JN, Sørensen JB: Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. Cancer Chemother Pharmacol 69:289-299, 2012
63. Boca SM, Kinzler KW, Velculescu VE, et al: Patient-oriented gene set analysis for cancer mutation data. Genome Biol 11:R112, 2010
64. Stransky N, Egloff AM, Tward AD, et al: The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157-1160, 2011
65. Ellis MJ, Ding L, Shen D, et al: Wholegenome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-360, 2012
66. Malinowsky K, Wolff C, Ergin B, et al: Deciphering signaling pathways in clinical tissues for personalized medicine using protein microarrays. J Cell Physiol 225:364-370, 2010
67. De Palma M, Hanahan D: The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities. Mol Oncol 6:111-127, 2012
68. Shah SP, Roth A, Goya R, et al: The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 486:395-399, 2012
69. Gajiwala KS, Wu JC, Christensen J, et al: KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A 106:1542-1547, 2009
70. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73, 2005
71. Choi YL, Soda M, Yamashita Y, et al: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734-1739, 2010
72. Yauch RL, Dijkgraaf GJ, Alicke B, et al: Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326:572-574, 2009
73. Garraway LA, Jänne PA: Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2:214-226, 2012
74. Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-3096, 2011
75. Diaz LA Jr, Williams RT, Wu J, et al: The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537-540, 2012
76. Misale S, Yaeger R, Hobor S, et al: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532-536, 2012
77. Vilar E, Tabernero J: Cancer: Pinprick diagnostics. Nature 486:482-483, 2012
78. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043, 2007
79. Arcila ME, Oxnard GR, Nafa K, et al: Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acidbased assay. Clin Cancer Res 17:1169-1180, 2011
80. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26, 2011
81. Janjigian YY, Groen HJ, Horn L, et al: Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 29:482s, 2011 (suppl. abstract 7525)
82. Olson EM, Lin NU, Krop IE, et al: The ethical use of mandatory research biopsies. Nat Rev Clin Oncol 8:620-625, 2011
83. El-Osta H, Hong D, Wheler J, et al: Outcomes of research biopsies in phase I clinical trials: The MD Anderson Cancer Center experience. Oncologist 16:1292-1298, 2011
84. Lipson D, Capelletti M, Yelensky R, et al: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18:382-384, 2012
85. Ng PC, Henikoff S: SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31:3812-3814, 2003
86. Yap TA, Sandhu SK, Workman P, et al: Envisioning the future of early anticancer drug development. Nat Rev Cancer 10:514-523, 2010
87. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al: Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877-4883, 2010
88. Tsimberidou AM, Iskander NG, Hong DS, et al: Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center initiative. J Clin Oncol 29:165s, 2011 (suppl; abstr CRA2500)
89. Wagle N, Berger MF, Davis MJ, et al: Highthroughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2:82-93, 2012
90. Roychowdhury S, Iyer MK, Robinson DR, et al: Personalized oncology through integrative highthroughput sequencing: A pilot study. Sci Transl Med 3:111ra121, 2011
91. Welch JS, Westervelt P, Ding L, et al: Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 305:1577-1584, 2011
92. Rodón J, Saura C, Dienstmann R, et al: Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol 9:359-366, 2012
93. Barker AD, Sigman CC, Kelloff GJ, et al: I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86:97-100, 2009
94. Kim ES, Herbst RS, Wistuba II, et al: The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov 1:44-53, 2011
95. Coyle VM, Johnston PG: Genomic markers for decision making: What is preventing us from using markers? Nat Rev Clin Oncol 7:90-97, 2010
96. McGuire AL, Caulfield T, Cho MK: Research ethics and the challenge of whole-genome sequencing. Nat Rev Genet 9:152-156, 2008
97. Marusyk A, Almendro V, Polyak K: Intratumour heterogeneity: A looking glass for cancer? Nat Rev Cancer 12:323-334, 2012
98. Shah SP, Kö bel M, Senz J, et al: Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 360:2719-2729, 2009
99. Dalgliesh GL, Furge K, Greenman C, et al: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360-363, 2010
100. Wiegand KC, Shah SP, Al-Agha OM, et al: ARID1A mutations in endometriosis-Associated ovarian carcinomas. N Engl J Med 363:1532-1543, 2010
101. Jones S, Wang TL, Shih IeM, et al: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330:228-231, 2010
102. Varela I, Tarpey P, Raine K, et al: Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469:539-542, 2011
103. Baylin SB, Jones PA: A decade of exploring the cancer epigenome: Biological and translational implications. Nat Rev Cancer 11:726-734, 2011
104. Sandoval J, Esteller M: Cancer epigenomics: Beyond genomics. Curr Opin Genet Dev 22:50-55, 2012
105. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
106. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
107. Ascierto PA, Berking C, Agarwala SS, et al: Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol 30:542s, 2012 (suppl; abstr 8511)
108. Dickson MA, Keohan ML, Tap WD, et al: Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-Amplified liposarcoma. J Clin Oncol 30:630s, 2012 (suppl; abstr 10002)
109. Shaw JA, Page K, Blighe K, et al: Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 22:220-231, 2012
110. Higgins MJ, Jelovac D, Barnathan E, et al: Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 18:3462-3469, 2012